Back to News
Market Impact: 0.35
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
Source: GlobeNewswire
Healthcare & BiotechRegulation & Legislation
MAIA received FDA clearance for its amended investigational new drug (IND) submission. The clearance highlights improvements in the company’s manufacturing capabilities and operating efficiencies, supporting continued clinical development progress.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
MAIA0.65
More News
- Congress passes sweeping US sanctions bill targeting Russia
- House Passes Bill Allowing Trump Tariffs on Russian Oil Buyers
- Fed Rate Hike Looms as Retail Sales Surge
- OpenAI discloses six more instances of ’concerning’ AI model behavior
- The Fed decision, Clarity Act fails in Senate, Ford's truck prices and more in Morning Squawk
- Snap tries to bring AR glasses to enterprise market, partnering with Nvidia, AWS and Salesforce